‘Detoxification’ of gut-derived toxins and microbial products from gut-derived microbes is a major role of the liver. While the full repertoire of gut-derived microbial products that reach the liver in health and disease is yet to be explored, the levels of bacterial lipopolysaccharide (LPS), a component of Gram-negative bacteria, is increased in the portal and/or systemic circulation in several types of chronic liver diseases. Increased gut permeability and LPS play a role in alcoholic liver disease where alcohol impairs the gut epithelial integrity through alterations in tight junction proteins. In addition, non-alcoholic fatty liver disease is also associated with increased serum LPS levels and activation of the pro-inflammatory cascade plays a central role in disease progression. Microbial danger signals are recognized by pattern recognition receptors such as the Toll-like receptor 4 (TLR4). Increasing evidence suggests that TLR4-mediated signaling via the MyD88-dependent or MyD88-independent pathways may play different roles in liver diseases associated with increased LPS exposure of the liver as a result of gut permeability. For example, we showed that in alcoholic liver disease, the MyD88-independent, IRF3-dependent TLR4 cascade plays a role in steatosis and inflammation. Our recent data demonstrate that chronic alcohol exposure in the liver leads to sensitization of Kupffer cells to LPS via a mechanism involving upregulation of microRNA-155 in Kupffer cells. Thus, understanding the cell-specific recognition and intracellular signaling events in sensing gut-derived microbes will help to achieve an optimal balance in the gut-liver axis and ameliorate liver diseases.

Keywords:
Gut permeability, Lipopolysaccharide sensitization, Toll-like receptor 4, microRNA
1.
Szabo G, Bala S: Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010;16;1321–1329.
2.
Son G, Kremer M, Hines IN: Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract 2011 (in press).
3.
Artis D: Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411–420.
4.
Robinson CJ, Bohannan BJM, Young VB: From structure to function: the ecology of host-associated microbial communities. Microbiol Mol Biol Rev 2010;74:453–476.
5.
Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA: Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010;7:1065–1075.
6.
Szabo G: LPS in Liver Disease. Falk Meeting, 2008.
7.
Wang HJ, Zakhari S, Jung MK: Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World J Gastroenterol 2010;16:1304–1313.
8.
Shao B, Lu M, Katz SC, Varley AW, Hardwick J, Rogers TE, Ojogun N, Rockey DC, DeMatteo RP, Munford RS: A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen. J Biol Chem 2007;282:13726–13735.
9.
Lu M, Varley AW, Ohta S, Hardwick J, Munford RS: Host inactivation of bacterial lipopolysaccharide prevents prolonged tolerance following Gram-negative bacterial infection. Cell Host Microbe 2008;4:293–302.
10.
Bjarnason I, Peters TJ, Wise RJ: The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984;1:179–182.
11.
Nanji AA, Khettry U, Sadrzadeh SM, Yamanaka T: Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol 1993;142:367–373.
12.
Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, Szabo G: Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007;133:1627–1636.
13.
Douek DC, Roederer M, Koup RA: Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009;60:471–484.
14.
Barbier de La Serre C, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould HE: Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 2010;299:G440–G448.
15.
Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R: Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009;106:2365–2370.
16.
Yan AW, E Fouts D, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto HE, Nelson KA, Brenner D, Schnabl B: Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53:96–105.
17.
Varol C, Zigmond E, Jung S: Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat Rev Immunol 2010;10:415–426.
18.
Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, Fehling HJ, Hardt WD, Shakhar G, Jung S: Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009;31:502–512.
19.
Rao RK, Seth A, Sheth P: Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;286:G881–G884.
20.
Rao RK: Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. Methods Mol Biol 2008;447:171–183.
21.
Tang Y, Forsyth CB, Farhadi A, Rangan J, Jakate S, Shaikh M, Banan A, Fields JZ, Keshavarzian A: Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol Clin Exp Res 2009;33:1220–1230.
22.
Tang Y, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ, Keshavarzian A: Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 2008;32:355–364.
23.
Kumagai Y, Akira S: Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol 2010;125:985–992.
24.
McGettrick AF, O’Neill, LA: Localisation and trafficking of Toll-like receptors: an important mode of regulation. Curr Opin Immunol 2010;22:20–27.
25.
Szabo G, Dolganiuc A, Mandrekar P: Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006;44:287–298.
26.
Szabo G, Mandrekar P: Toll-like receptors. Signal Pathways Liver Dis 2010;8:149–159.
27.
Schroder K, Tschopp J: The inflammasomes. Cell 2010;140:821–832.
28.
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085–2088.
29.
Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189:1777–1782.
30.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide and lipopolysaccharide-binding protein. Science 1990;249:1431–1433.
31.
Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K, Akira S: Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887–5894.
32.
Bode C, Bode JC: Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003;17:575–592.
33.
Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218–224.
34.
Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG: Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994;20:453–460.
35.
Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, Kurt-Jones E, Szabo G: The critical role of toll-like receptor (TLR)-4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008;48:1224–1231.
36.
Petrasek J, Dolganiuc A, Nath B, Hritz I, Kodys K, Catalano, Kurt-Jones E, Mandrekar P, Szabo G: Hepatocyte-specific IRF3 and type I interferons are protective in alcohol-induced liver injury I mice via cross-talk with macrophages. Hepatology 2011 (in press).
37.
DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE: Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008;83:460–469.
38.
Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P: Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009;33:1836–1846.
39.
Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A: Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease. Liver Transpl 2009;49:1877–1887.
40.
Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M: Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571–579.
41.
Piao W, Song C, Chen H, Diaz MA, Wahl LM, Fitzgerald KA, Li L, Medvedev AE: Endotoxin tolerance dysregulates MyD88- and Toll/IL-1R domain-containing adapter inducing IFN-β-dependent pathways and increases expression of negative regulators of TLR signaling. J Leukoc Biol 2009;86:863–875.
42.
Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN: Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase-1 activation in endotoxin-tolerant cells. J Immunol 2002;169:5209–5216.
43.
Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G: The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol 2009;183:1320–1327.
44.
Tili E, Michaille JJ, Cimino A, et al: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007;179:5082–5089.
45.
Bala S, Marcos-Martin M, Kodys K, Petrasek J, Catalano D, Mandrekar P, Szabo G: Upregulation of microRNA-155 in macrophages contributes to increased TNF production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011;286:1436–1444.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.